Log in
Enquire now
‌

US Patent 7402431 T-cell therapy formulation

Patent 7402431 was granted and assigned to Immunovative Therapies on July, 2008 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent
1

Patent attributes

Current Assignee
Immunovative Therapies
Immunovative Therapies
1
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
1
Patent Number
74024311
Patent Inventor Names
Michael Har-Noy1
Date of Patent
July 22, 2008
1
Patent Application Number
110690101
Date Filed
March 1, 2005
1
Patent Citations Received
‌
US Patent 11833173 Th1 vaccination priming for active immunotherapy
2
‌
US Patent RE49847 Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
3
‌
US Patent 11883490 Induction of IL-12 using immunotherapy
4
‌
US Patent 11872249 Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
5
Patent Primary Examiner
‌
Michail A Belyavskyi
1
Patent abstract

Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation signals upon cross-linking and mixing the labeled cells with biodegradable nanospheres or microspheres coated with a material capable of cross-linking the agents attached to the T-cell surface moieties. Alternatively, the formulation may be made by mixing a population of T-cells with biodegradable nanospheres or microspheres coated with a first material and one or more second materials. The first material binds the second material and the second material has reactivity for surface moieties on the T-cells and the interaction of the second materials with the T-cells causes the activation of the T-cells. In either method, the mixture of T-cells and biodegradable spheres are suspended in a medium suitable for infusion, and the mixture is packaged in a container.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7402431 T-cell therapy formulation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.